DE60239073D1 - Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren - Google Patents

Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren

Info

Publication number
DE60239073D1
DE60239073D1 DE60239073T DE60239073T DE60239073D1 DE 60239073 D1 DE60239073 D1 DE 60239073D1 DE 60239073 T DE60239073 T DE 60239073T DE 60239073 T DE60239073 T DE 60239073T DE 60239073 D1 DE60239073 D1 DE 60239073D1
Authority
DE
Germany
Prior art keywords
anthranilic acid
treatment
tyrosine kinase
kinase inhibitors
receptor tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239073T
Other languages
German (de)
English (en)
Inventor
Guido Bold
Pascal Furet
Paul William Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60239073D1 publication Critical patent/DE60239073D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60239073T 2001-11-08 2002-11-07 Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren Expired - Lifetime DE60239073D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126902.6A GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds
PCT/EP2002/012444 WO2003040102A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60239073D1 true DE60239073D1 (de) 2011-03-10

Family

ID=9925448

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239073T Expired - Lifetime DE60239073D1 (de) 2001-11-08 2002-11-07 Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren

Country Status (28)

Country Link
US (2) US7091224B2 (enExample)
EP (1) EP1446382B1 (enExample)
JP (1) JP2005511602A (enExample)
KR (1) KR100602977B1 (enExample)
CN (1) CN1300113C (enExample)
AT (1) ATE496889T1 (enExample)
AU (1) AU2002351909B2 (enExample)
BR (1) BR0213970A (enExample)
CA (1) CA2463968C (enExample)
CO (1) CO5580823A2 (enExample)
DE (1) DE60239073D1 (enExample)
ES (1) ES2360283T3 (enExample)
GB (1) GB0126902D0 (enExample)
HR (1) HRP20040411A2 (enExample)
IL (1) IL161747A0 (enExample)
MX (1) MXPA04004391A (enExample)
NO (1) NO327231B1 (enExample)
NZ (1) NZ532590A (enExample)
PE (1) PE20030714A1 (enExample)
PL (1) PL368416A1 (enExample)
PT (1) PT1446382E (enExample)
RU (1) RU2318811C2 (enExample)
SA (1) SA02230412B1 (enExample)
TW (1) TWI260222B (enExample)
UA (1) UA77446C2 (enExample)
WO (1) WO2003040102A1 (enExample)
YU (1) YU36004A (enExample)
ZA (1) ZA200402940B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1820795A4 (en) 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101265274B (zh) * 2007-02-16 2013-09-04 中国医学科学院药物研究所 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途
AR073216A1 (es) 2008-08-27 2010-10-20 Leo Pharma As Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0850222B1 (en) * 1996-06-29 2003-05-28 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20030714A1 (es) 2003-10-13
MXPA04004391A (es) 2005-12-12
KR20050044382A (ko) 2005-05-12
HRP20040411A2 (en) 2005-04-30
JP2005511602A (ja) 2005-04-28
NO327231B1 (no) 2009-05-18
BR0213970A (pt) 2004-08-31
US7091224B2 (en) 2006-08-15
RU2318811C2 (ru) 2008-03-10
UA77446C2 (en) 2006-12-15
RU2004117543A (ru) 2006-01-10
CA2463968C (en) 2011-02-22
CO5580823A2 (es) 2005-11-30
CN1300113C (zh) 2007-02-14
GB0126902D0 (en) 2002-01-02
US7482369B2 (en) 2009-01-27
TW200300087A (en) 2003-05-16
ZA200402940B (en) 2005-02-10
CA2463968A1 (en) 2003-05-15
SA02230412B1 (ar) 2007-07-31
ES2360283T3 (es) 2011-06-02
KR100602977B1 (ko) 2006-07-20
NZ532590A (en) 2005-12-23
YU36004A (sh) 2006-08-17
TWI260222B (en) 2006-08-21
NO20042187L (no) 2004-05-26
US20060178409A1 (en) 2006-08-10
EP1446382A1 (en) 2004-08-18
PT1446382E (pt) 2011-05-03
IL161747A0 (en) 2005-11-20
WO2003040102A1 (en) 2003-05-15
US20050096356A1 (en) 2005-05-05
EP1446382B1 (en) 2011-01-26
PL368416A1 (en) 2005-03-21
CN1585750A (zh) 2005-02-23
AU2002351909B2 (en) 2007-04-26
ATE496889T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
ATE496889T1 (de) Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren
ES2517690T3 (es) Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina
ES2328471T3 (es) Pirimidinas aril sustituidas y uso de las mismas.
DE60028740D1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
RU2004132844A (ru) Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов
RU2006105716A (ru) Производные пиридазина и их применение в качестве терапевтических средств
CA2342250A1 (en) Quinazoline derivatives as medicaments
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
PT1236726E (pt) Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo
MY126862A (en) Purine derivatives inhibitors of tyrosine protein kinase syk
JP2001316267A (ja) ドーパミンアゴニスト療法に付随するジスキネジーを処置するためにａｍｐａレセプターアンタゴニストを投与する方法
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
PT1378510E (pt) Derivados de triazaespiro [5.5] undecano e farmacos que os contem como componentes activos
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PL2004653T3 (pl) 3-Podstawione N-(arylo- lub heteroarylo)-pirazo[1,5-a]pirymidyny jako inhibitory kinazy
ES2821102T3 (es) Derivados de azaquinazolincarboxamida
EA200400936A1 (ru) ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
DE60327652D1 (de) Diarylureidoderivate und deren medizinische verwendung
BRPI0413584A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
MY136322A (en) Anthranilic acid amides and pharmaceutical use thereof
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2